TNF Pharmaceuticals is set to initiate fully funded mid-stage Phase II clinical trials of its lead programme, MYMD-1, targeting sarcopenia.
MYMD-1, a small molecule therapy, has shown positive results in regulating the immuno-metabolic system by blocking TNF-alpha activity.
Go deeper with GlobalData
The upcoming studies aim to build on the positive results from an earlier Phase II trial, which demonstrated MYMD-1’s efficacy in reducing chronic inflammation markers in sarcopenia / frailty.
TNF Pharmaceuticals president and chief medical officer Mitchell Glass said: “In our view, MYMD-1, if approved, could be the first orally administered TNF-alpha inhibitor drug and the first and only therapy for sarcopenia, a common age-related disorder that causes a prolonged decline in physical function.
“As we prepare for our next fully funded clinical studies in sarcopenia/frailty, we also have open INDs for Phase II trials of MYMD-1 in two additional chronic inflammatory conditions, rheumatoid arthritis (RA) and Hashimoto’s thyroiditis, which we could pursue with the support of non-dilutive domestic and/or international development partnerships.
“A partner outside of the US could potentially help us accelerate the timeline to commercialisation of our lead asset.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMYMD-1 targets TNF-alpha, a key protein in inflammation and autoimmunity.
A small Phase II study that was concluded last year showed that it significantly reduced serum levels of chronic inflammatory markers, without any treatment-related adverse events.
The drug’s ability to cross the blood-brain barrier also positions it as a potential treatment for rheumatoid arthritis and Hashimoto’s thyroiditis.
MYMD-1’s reduction of inflammation biomarkers, including TNF-α, sTNFR1, and IL-6, marks a significant step forward in addressing sarcopenia.
TNF Pharmaceuticals also has a secondary drug platform, Supera-CBD, a synthetic CBD analogue.
Supera-CBD is being developed for pain, epilepsy, anxiety and depression, and potentially opioid addiction treatment, given its binding profile with opioid receptors.
